Theralink appoints Faith Zaslavsky as CEO; Mick Ruxin becomes CMO

THERALINK TECHNOLOGIES, INC.

Faith Zaslavsky appointed CEO effective June 26, 2023; previously President and COO since December 2022.
Former CEO Mick Ruxin transitions to Chief Medical Officer.
Company is in process of merging with IMAC Holdings, Inc. (NASDAQ: BACK).
Zaslavsky has over 23 years of genomics experience, including commercializing BRCA tests.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Faith Zaslavsky

Chief Executive Officer

THERALINK TECHNOLOGIES, INC.

Effective: 2023-06-26
Filed: June 29, 2023, 7:59 PM ET

Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023.

Role change

Mick Ruxin

Chief Medical Officer

THERALINK TECHNOLOGIES, INC.

Filed: June 29, 2023, 7:59 PM ET

The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Faith Zaslavsky was appointed as Chief Executive Officer at THERALINK TECHNOLOGIES, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mick Ruxin changed role as Chief Medical Officer at THERALINK TECHNOLOGIES, INC..

Action: transitioned
Role: Chief Medical Officer

Exact text from the filing

The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-23-022908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.